XML 44 R26.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Stock Plans and Management Compensation | 12 Months Ended
--- | ---
Dec. 31, 2017
Share-based Compensation [Abstract] |
Stock Plans and Management Compensation | Stock Plans and Management Compensation Under the Brunswick Corporation 2014 Stock Incentive Plan, the Company may grant stock options, stock appreciation rights (SARs), non-vested stock awards and performance awards to executives, other employees and non-employee directors, with shares from treasury shares and from authorized, but unissued, shares of common stock initially available for grant, in addition to: (i) the forfeiture of past awards; (ii) shares not issued upon the net settlement of SARs; or (iii) shares delivered to or withheld by the Company to pay the withholding taxes related to awards. As of December 31, 2017, 5.4 million shares remained available for grant. Share information includes all outstanding awards for both continuing and discontinued operations. Non-Vested Stock Awards The Company grants both stock-settled and cash-settled non-vested stock units and awards to key employees as determined by management and the Human Resources and Compensation Committee of the Board of Directors. Non-vested stock units and awards have vesting periods of three years. Non-vested stock units and awards are eligible for dividends, which are reinvested, and are non-voting. All non-vested units and awards have restrictions on the sale or transfer of such awards during the vesting period. Generally, grants of non-vested stock units and awards are forfeited if employment is terminated prior to vesting. Non-vested stock units and awards vest pro rata over one year if (i) the grantee has attained the age of 62, or (ii) the grantee's age plus total years of service equals 70 or more. The Company recognizes the cost of non-vested stock units and awards on a straight-line basis over the requisite service period. Additionally, cash-settled non-vested stock units and awards are recorded as a liability on the balance sheet and adjusted to fair value each reporting period through stock compensation expense. During the years ended December 31, 2017, 2016 and 2015, the Company charged $11.1 million, $10.1 million and $12.9 million, respectively, to compensation expense for non-vested stock units and awards. The related income tax benefit recognized in 2017, 2016 and 2015 was $4.2 million, $3.9 million and $4.9 million, respectively. The fair value of shares vested during 2017, 2016 and 2015 was $12.1 million, $13.8 million and $20.4 million respectively. The weighted average price per Non-vested stock award at grant date was $60.30, $40.01 and $53.77 for awards granted in 2017, 2016 and 2015, respectively. Non-vested stock award activity for the year ended December 31, 2017 was as follows:
(in thousands, except grant date fair value) | Non-vested Stock Award Activity |  | Weighted Average Grant Date Fair Value
Non-vested awards, unvested at January 1 | 379 |  |  | $ | 43.35 |
Awarded | 240 |  |  | 60.30 |
Forfeited | (25 | ) |  | 50.19 |
Vested | (218 | ) |  | 46.48 |
Non-vested awards, unvested at December 31 | 376 |  |  | $ | 51.69 |
As of December 31, 2017, there was $7.4 million of total unrecognized compensation expense related to non-vested stock awards. The Company expects this expense to be recognized over a weighted average period of 1.3 years. Stock Options and SARs Through 2004, the Company issued stock options, and between 2005 and 2012, the Company issued stock-settled SARs. Generally, stock options and SARs are exercisable over a period of 10 years, or as otherwise determined by management and the Human Resources and Compensation Committee of the Board of Directors, and subject to vesting periods of generally 4 years. However, with respect to stock options and SARs, all grants vest immediately: (i) in the event of a change in control; (ii) upon death or disability of the grantee; or (iii) with respect to awards granted prior to 2008, upon the sale or divestiture of the business unit to which the grantee is assigned. In addition, grantees continue to vest in accordance with the vesting schedule even upon termination if (i) the grantee has attained the age of 62, or (ii) the grantee's age plus total years of service equals 70 or more. An additional provision applies that prorates the grant in the event of termination prior to the first anniversary of the date of grant, provided the participant had met the appropriate retirement age definition of rule of 70 or age 62. SARs and stock option activity for all plans for the years ended December 31, 2017, 2016 and 2015, was as follows:
| 2017 |  | 2016 |  | 2015
(in thousands, except exercise price and terms) | SARs/Stock Options Outstanding |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Term |  | Aggregate Intrinsic Value |  | SARs/Stock Options Outstanding |  | Weighted Average Exercise Price |  | Aggregate Intrinsic Value |  | SARs/Stock Options Outstanding |  | Weighted Average Exercise Price |  | Aggregate Intrinsic Value
Outstanding on January 1 | 978 |  |  | $ | 14.43 |  |  |  |  |  |  | 2,234 |  |  | $ | 15.78 |  |  |  |  | 2,705 |  |  | $ | 16.91 |  |  |
Exercised | (352 | ) |  | $ | 14.37 |  |  |  |  | $ | 16,071 |  |  | (1,252 | ) |  | $ | 16.76 |  |  | $ | 32,096 |  |  | (464 | ) |  | $ | 22.15 |  |  | $ | 14,615 |
Forfeited | (32 | ) |  | $ | 15.76 |  |  |  |  |  |  | (4 | ) |  | $ | 38.42 |  |  |  |  | (7 | ) |  | $ | 29.99 |  |  |
Outstanding on December 31 | 594 |  |  | $ | 14.40 |  |  | 2.3 years |  | $ | 24,261 |  |  | 978 |  |  | $ | 14.43 |  |  | $ | 39,228 |  |  | 2,234 |  |  | $ | 15.78 |  |  | $ | 77,580 |
Exercisable on December 31 | 594 |  |  | $ | 14.40 |  |  | 2.3 years |  | $ | 24,261 |  |  | 978 |  |  | $ | 14.43 |  |  | $ | 39,228 |  |  | 2,151 |  |  | $ | 15.47 |  |  | $ | 75,372 |
Vested and expected to vest on December 31 | 594 |  |  | $ | 14.40 |  |  | 2.3 years |  | $ | 24,261 |  |  | 978 |  |  | $ | 14.43 |  |  | $ | 39,228 |  |  | 2,234 |  |  | $ | 15.78 |  |  | $ | 77,580 |
The following table summarizes information about SARs and stock options outstanding as of December 31, 2017:
|  | Outstanding |  | Exercisable
Range of Exercise Price |  | Number (in thousands) |  | Weighted Average Remaining Years of Contractual Life |  | Weighted Average Exercise Price |  | Number (in thousands) |  | Weighted Average Remaining Years of Contractual Life |  | Weighted Average Exercise Price
$3.37 to $5.86 |  | 130 |  |  | 1.3 | years |  | $ | 5.42 |  |  | 130 |  |  | 1.3 | years |  | $ | 5.42 |
$5.87 to $17.06 |  | 244 |  |  | 2.0 | years |  | $ | 11.99 |  |  | 244 |  |  | 2.0 | years |  | $ | 11.99 |
$17.07 to $23.79 |  | 220 |  |  | 3.3 | years |  | $ | 22.36 |  |  | 220 |  |  | 3.3 | years |  | $ | 22.36 |
Stock option and SARs expense was immaterial for all periods presented. Performance Awards In February 2017, 2016 and 2015, the Company granted performance shares to certain senior executives. Performance share awards are based on three performance measures: a cash flow return on investment (CFROI) measure, an operating margin (OM) measure and a total shareholder return (TSR) modifier. Performance shares are earned based on a three-year performance period commencing at the beginning of the calendar year of each grant. The performance shares earned are then subject to a TSR modifier based on stock returns measured against stock returns of a predefined comparator group over a three-year performance period. Additionally, in February 2017, 2016 and 2015, the Company granted 26,300, 37,430 and 22,990 performance shares, respectively, to certain officers and certain senior managers based on the respective measures and performance periods described above but excluding a TSR modifier. The fair values of the senior executives' performance share award grants with a TSR modifier at the grant date in 2017, 2016 and 2015 were $64.82, $38.54 and $56.17, respectively, which were estimated using the Monte Carlo valuation model, and incorporated the following assumptions:
| 2017 |  | 2016 |  | 2015
Risk-free interest rate | 1.5 | % |  | 0.8 | % |  | 1.0 | %
Dividend yield | 1.1 | % |  | 1.0 | % |  | 0.9 | %
Volatility factor | 38.3 | % |  | 40.8 | % |  | 39.2 | %
Expected life of award | 2.9 years |  |  | 2.9 years |  |  | 2.9 years |
The fair value of certain officers' and certain senior managers' performance awards granted based solely on the CFROI and OM performance factors was $58.77, $37.76 and $52.39, which was equal to the stock price on the date of grant in 2017, 2016 and 2015, respectively, less the present value of dividend payments over the vesting period. The Company recorded compensation expense related to performance awards of $6.7 million, $6.0 million and $7.9 million in 2017, 2016 and 2015, respectively. The related income tax benefit recognized in 2017, 2016 and 2015 was $2.6 million, $2.3 million and $3.0 million, respectively. The fair value of awards vested during 2017, 2016 and 2015 was $5.5 million, $9.1 million and $7.5 million, respectively. Performance award activity for the year ended December 31, 2017 was as follows:
(in thousands, except grant date fair value) | Performance Awards |  | Weighted Average Grant Date Fair Value
Performance awards, unvested at January 1 | 91 |  |  | $ | 43.91 |
Awarded | 114 |  |  | 63.43 |
Forfeited | (4 | ) |  | 47.10 |
Vested and earned | (99 | ) |  | 59.34 |
Performance awards, unvested at December 31 | 102 |  |  | $ | 50.69 |
As of December 31, 2017, the Company had $2.3 million of total unrecognized compensation expense related to performance awards. The Company expects this expense to be recognized over a weighted average period of 1.5 years. Excess Tax Benefits/Shortfalls For tax purposes, share-based compensation expense is deductible in the year of exercise or release based on the intrinsic value of the award on the date of exercise or release. For financial reporting purposes, share-based compensation expense is based upon grant-date fair value, which is amortized over the vesting period. Excess or "windfall" tax benefits represent the excess tax deduction received by the Company resulting from the difference between the share-based compensation expense deductible for tax purposes and the share-based compensation expense recognized for financial reporting purposes. Conversely, the Company may recognize a tax "shortfall" in circumstances when share-based expense recognized for reporting purposes exceeds the expense deductible for tax purposes. Windfall tax benefits and shortfalls are recorded directly to Income tax provision on the Company's Consolidated Statement of Operations. Windfall tax benefits for the years ended December 31, 2017, 2016 and 2015 were $8.0 million, $13.4 million and $7.0 million, respectively. Director Awards The Company issues stock awards to non-employee directors in accordance with the terms and conditions determined by the Nominating and Corporate Governance Committee of the Board of Directors. A portion of each director’s annual fee is paid in Brunswick common stock, the receipt of which may be deferred until a director retires from the Board of Directors. Each director may elect to have the remaining portion paid in cash, in Brunswick common stock distributed at the time of the award, or in deferred Brunswick common stock units with a 20 percent premium.

X
- Definition The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -URI http://asc.fasb.org/subtopic&trid=2208855 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_ShareBasedCompensationAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration